Literature DB >> 58716

Reversibility and irreversibility of liver tumors in mice induced by the alpha isomer of 1,2,3,4,5,6-hexachlorocyclohexane.

N Ito, M Hananouchi, S Sugihara, T Shirai, H Tsuda.   

Abstract

The characteristics of liver tumors in mice induced by the alpha isomer of 1,2,3,4,5,6-hexachlorocyclohexane (alpha-BHC), were studied with emphasis on their reversibility of irreversibility. Male 8-week-old DDY mice were fed basal diet supplemented with 500 ppm of alpha-BHC for 16, 20, 24, and 36 weeks and then were fed basal diet without alpha-BHC for 4, 8, 12, 16, 24, or 36 weeks. At various intervals, 13 to 20 mice were killed for light and electron microscopic observations. The incidences of liver tumors in mice induced by alpha-BHC increased progressively on continuous administration of alpha-BHC, but when its administration was discontinued some tumors disappeared. Histologically, after alpha-BHC administration for 24 weeks, most tumors were nodular hyperplasias, and there were only a few well-differentiated hepatocellular carcinomas. However, 60 or 72 weeks after the beginning of the experiment, most of the liver tumors were hepatocellular carcinomas and there were only a few nodular hyperplasias. At a later stage, 60 or 72 weeks, the liver parenchymal tissue in nontumorous areas was essentially normal, but small foci were occasionally seen in nontumorous areas that were composed of remaining hyperplastic nodular cells, phagocytic cells, Kupffer cells, and leukocytes. These findings suggest that the reversible tumors were usually nodular hyperplasias whereas the irreversible tumors were hepatocellular carcinomas. After alpha-BHC administration was stopped, many mesenchymal cells infiltrated the nodular hyperplastic lesions, and degenerated liver cells were found. These observations indicate that mesenchymal cell elements may be important in reversing the growth of liver tumors induced by alpha-BHC.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 58716

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  The stability of events in the natural history of neoplasia.

Authors:  H C Pitot
Journal:  Am J Pathol       Date:  1977-12       Impact factor: 4.307

2.  alpha(2)-Macroglobulin: a novel cytochemical marker characterizing preneoplastic and neoplastic rat liver lesions negative for hitherto established cytochemical markers.

Authors:  Tokuo Sukata; Satoshi Uwagawa; Keisuke Ozaki; Kayo Sumida; Kaoru Kikuchi; Masahiko Kushida; Koichi Saito; Keiichirou Morimura; Kenji Oeda; Yasuyoshi Okuno; Nobuyoshi Mikami; Shoji Fukushima
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

3.  Characteristic upregulation of glucose-regulated protein 78 in an early lesion negative for hitherto established cytochemical markers in rat hepatocarcinogenesis.

Authors:  Tokuo Sukata; Satoshi Uwagawa; Keisuke Ozaki; Kayo Sumida; Masahiko Kushida; Anna Kakehashi; Hideki Wanibuchi; Kaori Miyata; Keiko Ogata; Shoji Fukushima
Journal:  J Toxicol Pathol       Date:  2009-12-21       Impact factor: 1.628

4.  Further study of alpha benzene hexachloride inhibition of aflatoxin B1 hepatocarcinogenesis in rats.

Authors:  S Angsubhakorn; N Bhamarapravati; K Romruen; S Sahaphong; W Thamavit; M Miyamoto
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

5.  Oxidative stress in the carcinogenicity of chemical carcinogens.

Authors:  Anna Kakehashi; Min Wei; Shoji Fukushima; Hideki Wanibuchi
Journal:  Cancers (Basel)       Date:  2013-10-28       Impact factor: 6.639

6.  A carcinogenic potency database of the standardized results of animal bioassays.

Authors:  L S Gold; C B Sawyer; R Magaw; G M Backman; M de Veciana; R Levinson; N K Hooper; W R Havender; L Bernstein; R Peto
Journal:  Environ Health Perspect       Date:  1984-12       Impact factor: 9.031

7.  Synergistic effects of low-dose hepatocarcinogens in induction of glutathione S-transferase P-positive foci in the rat liver.

Authors:  R Hasegawa; M Mutai; K Imaida; H Tsuda; S Yamaguchi; N Ito
Journal:  Jpn J Cancer Res       Date:  1989-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.